Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus LAMICTAL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus LAMICTAL XR.
DIACOMIT vs LAMICTAL XR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
FDA-approved for adjunctive therapy with clobazam for seizures associated with Dravet syndrome in patients 6 months to less than 18 years of age weighing ≥7 kgOff-label: other refractory epilepsies, status epilepticus
Adjunctive therapy for partial-onset seizures in patients aged ≥13 yearsAdjunctive therapy for primary generalized tonic-clonic seizures in patients aged ≥13 yearsConversion to monotherapy in patients aged ≥13 years with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproateAdjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged ≥13 yearsBipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital.
Extensively metabolized in the liver, primarily via CYP2C19 and CYP3A4; forms glucuronide conjugates.
Lamotrigine is primarily metabolized by hepatic glucuronidation via UDP-glucuronosyltransferases (UGT1A4, UGT2B7). It is not significantly metabolized by cytochrome P450 enzymes.
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces.
93-97% bound to serum albumin.
Approximately 55% bound to plasma proteins, primarily albumin.
0.7-1.0 L/kg; distributes into total body water, with extensive extravascular distribution.
Approximately 1.0-1.2 L/kg, indicating distribution into total body water and tissues.
Oral: 85-90% (absolute bioavailability after oral administration).
Oral bioavailability is approximately 98% for LAMICTAL XR extended-release tablets, with no significant food effect.
Not recommended in patients with severe renal impairment (CrCl < 30 mL/min). For mild to moderate impairment (CrCl 30-89 mL/min), use with caution and monitor for adverse effects; no specific dose adjustment established.
For patients with significant renal impairment (CrCl <30 mL/min): reduce maintenance dose by approximately 50%; administer with caution due to reduced clearance and potential accumulation of glucuronide metabolites.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce initial dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A), no adjustment required.
Child-Pugh Class A: reduce initial, escalation, and maintenance doses by approximately 25%; Child-Pugh Class B: reduce by 50%; Child-Pugh Class C: reduce by 75% (or avoid). Slower dose titration recommended.
Children aged 1-18 years: 10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
For children ≥2 years with epilepsy: weight-based dosing per Lamictal XR prescribing information; typical initial 0.3 mg/kg/day (divided once daily for XR) for first 2 weeks depending on concomitant medications; slow titration to maintenance doses approximately 4.5–11.5 mg/kg/day (max 400 mg/day) based on co-therapy (enzyme-inducing AEDs or valproate). Specific regimens require individual calculation.
Initiate at low end of dosing range due to possible reduced renal function and increased sensitivity; monitor renal function and adjust dose accordingly.
No specific dose adjustment solely for age; initiate and titrate cautiously. Monitor renal function and adjust accordingly. Use lowest effective maintenance dose due to potential decreased clearance and increased adverse effects.
None.
LAMICTAL XR is associated with a risk of life-threatening serious rashes including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death. The risk is increased in pediatric patients, with high starting doses, exceeding recommended dose escalation, and concomitant use of valproate.
["Somnolence and dizziness, particularly when used with clobazam","Neutropenia and thrombocytopenia","Risk of suicidal thoughts and behavior","Drug interactions due to CYP inhibition, especially with clobazam and valproate","Monitor for weight loss and growth retardation in children","Hyperammonemia when used with valproate"]
["Life-threatening serious rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash unless clearly not drug-related","Hemophagocytic lymphohistiocytosis (HLH); discontinue if HLH is suspected","Suicidal thoughts and behavior; monitor for worsening depression or suicidality","Aseptic meningitis; discontinue if symptoms suggest meningitis","Blood dyscrasias; monitor for signs of infection, bruising, or bleeding","Withdrawal seizures; taper dose gradually over at least 2 weeks","Status epilepticus; increased risk in patients with seizure disorders","Risk of rash in pediatric patients; stricter dosing guidelines","Interaction with oral contraceptives; may decrease lamotrigine efficacy","Concomitant use with valproate increases risk of rash; lower starting dose required"]
["Hypersensitivity to stiripentol or any component of the formulation","Prior history of psychotic episodes induced by antiepileptic drugs","Concomitant use with drugs that are CYP2C19 substrates (e.g., omeprazole) if not monitored"]
["History of hypersensitivity to lamotrigine or any component of the formulation","Use in patients with severe rash or hypersensitivity reactions to other antiepileptic drugs (cross-sensitivity)"]
Data Pending Review
Data Pending Review
Avoid food or milk within 1 hour before or after dose; food increases absorption and risk of adverse effects. Grapefruit may increase drug levels.
No specific food interactions are reported for lamotrigine. Grapefruit juice does not significantly affect lamotrigine metabolism. However, patients should maintain consistent dietary habits, and avoid rapid dietary changes that could affect GI motility or absorption. Alcohol may increase CNS depression.
Diacomit (stiripentol) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on animal reproduction studies and human data. First trimester exposure may be associated with major congenital malformations including cardiac defects and neural tube defects. In the second and third trimesters, exposure has been linked to impaired fetal growth and neurodevelopmental effects. Due to the risk of Dravet syndrome seizures, use during pregnancy should be considered only if the benefit to the mother outweighs the potential risk to the fetus.
Lamotrigine (LAMICTAL XR) is associated with a dose-dependent increased risk of major congenital malformations, particularly oral clefts (cleft lip/palate), in first trimester exposure. The absolute risk for any major malformation is approximately 2-4% at doses ≤200 mg/day, increasing to 4.5-9% at higher doses. Risk is lower than with valproate but higher than unexposed population. Third trimester exposure may increase risk of neonatal withdrawal or serotonin syndrome-like symptoms. Preterm birth and low birth weight have been reported.
Stiripentol is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.5–1.0 based on limited data. Because of the potential for serious adverse reactions in nursing infants, including sedation and poor feeding, breastfeeding is not recommended during treatment with Diacomit. The decision should be made considering the mother's clinical need and the infant's health status.
Lamotrigine is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.4-0.6 (range 0.2-1.0). Infant serum levels can reach 25-50% of maternal serum levels. Breastfeeding is generally considered compatible but requires monitoring for infant adverse effects such as rash, drowsiness, poor sucking, and apnea. The benefits of breastfeeding may outweigh risks if maternal treatment is necessary.
Pregnancy may reduce stiripentol plasma concentrations due to increased clearance, altered protein binding, and increased volume of distribution. Dose adjustments are recommended: start with 50 mg/kg/day in two divided doses, and increase as needed based on therapeutic drug monitoring and seizure control. Target trough concentrations of 10–20 mg/L. Adjust dose upward if trough levels fall below 10 mg/L. Monitor for toxicity, especially during the third trimester when clearance may increase.
Lamotrigine clearance increases significantly during pregnancy, particularly in the second and third trimesters, often requiring dose increases of 100-300% to maintain therapeutic levels. Serum concentrations should be monitored monthly during pregnancy, and dose adjusted to achieve pre-pregnancy target levels. Postpartum, clearance returns to baseline within 2 weeks, necessitating rapid dose reduction to avoid toxicity. A standard approach is to increase dose by 50% in the first trimester, double by third trimester, and taper back over 2-3 weeks postpartum.
Category C
Category C
DIACOMIT (stiripentol) is a CYP450 inhibitor; monitor levels of co-administered anticonvulsants. Dose must be adjusted with valproate. Avoid abrupt discontinuation. Use with caution in hematologic disorders; monitor CBC.
LAMICTAL XR (lamotrigine extended-release) is indicated for maintenance therapy of bipolar I disorder to delay the time to occurrence of mood episodes. Titrate slowly to minimize risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); typical starting dose 25-50 mg/day increased by 25-50 mg every 1-2 weeks. If valproate is coadministered, halve the dose and double the titration rate due to inhibition of lamotrigine clearance. Conversely, enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine, phenobarbital) require doubling of target dose. Monitor for rash, especially in first 2-8 weeks; any sign of rash should prompt immediate discontinuation unless clearly drug-unrelated. LAMICTAL XR has a longer half-life (about 33 hours) and allows once-daily dosing; do not chew or crush tablets.
Take DIACOMIT exactly as prescribed; do not stop suddenly.May cause drowsiness or dizziness; avoid driving until you know how it affects you.Report unusual bruising, bleeding, or signs of infection.Avoid alcohol.Do not take with food or milk; take on an empty stomach.
Swallow tablets whole; do not cut, chew, or crush.Take exactly as prescribed; do not stop abruptly without medical advice.Report any skin rash, hives, blisters, or mucosal lesions immediately.Contact doctor if you experience fever, swollen lymph nodes, or flu-like symptoms.If you miss a dose, skip it; do not double the next dose.Use reliable contraception if needed; this drug may reduce effectiveness of hormonal contraceptives.Avoid driving or hazardous activities until you know how this drug affects you.Keep a strict schedule; take at the same time each day.